Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
16 patents granted to the 6 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Tempest Therapeutics, Inc.’s names, not what it holds today.
Patents granted
16
16 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against none in 2024 and 4 in 2023
Applications published
25
1 of them in 2025
Names they are printed under
6
its own name, a former name
By yearGrantedApplications published
'14'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Organic fine chemistry7
Pharmaceuticals1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name6 counted
Tempest Therapeutics, Inc. its own name
named as the applicant on its applications, in US
12 publishedTEMPEST THERAPEUTICS, INC. its own name
US, as the owner printed on each patent
0 publishedMillendo Therapeutics, Inc. a former name
named as the applicant on its applications, in US
6 publishedOvaScience, Inc. a former name
US, as the owner printed on each patent
4 publishedMillendo Therapeutics, Inc a former name
US, as the owner printed on each patent
0 publishedOvaScience, Inc. a former name
named as the applicant on its applications, in US
3 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Feb 4, 2025 | 12,215,093 | Bicyclic carboxamides and methods of use thereof | Organic fine chemistry | TEMPEST THERAPEUTICS, INC. |
| Oct 24, 2023 | 11,795,156 | Bicyclic carboxamides and methods of use thereof | Organic fine chemistry | TEMPEST THERAPEUTICS, INC. |
| Aug 29, 2023 | 11,738,009 | Bicyclic compounds and their use in the treatment of cancer | Organic fine chemistry | TEMPEST THERAPEUTICS, INC. |
| Jun 6, 2023 | 11,666,557 | Triazolone compounds and uses thereof | Pharmaceuticals | TEMPEST THERAPEUTICS, INC. |
| May 2, 2023 | 11,638,704 | Bicyclic compounds and their use in the treatment of cancer | Organic fine chemistry | TEMPEST THERAPEUTICS, INC. |
| Oct 18, 2022 | 11,472,789 | Bicyclic carboxamides and methods of use thereof | Organic fine chemistry | TEMPEST THERAPEUTICS, INC. |
| Jul 20, 2021 | 11,066,405 | Bicyclic compounds and their use in the treatment of cancer | Organic fine chemistry | TEMPEST THERAPEUTICS, INC. |
| Apr 6, 2021 | 10,968,201 | Bicyclic carboxamides and methods of use thereof | Organic fine chemistry | TEMPEST THERAPEUTICS, INC. |
| Feb 25, 2020 | 10,568,871 | Triazolone compounds and uses thereof | Pharmaceuticals | TEMPEST THERAPEUTICS, INC. |
| Aug 28, 2018 | 10,059,660 | Solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and compositions, methods and kits related thereto | Pharmaceuticals | Millendo Therapeutics, Inc |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Nov 20, 2025 | 2025/0353829 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | Organic fine chemistry | Tempest Therapeutics, Inc. |
| May 9, 2024 | 2024/0150316 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | Organic fine chemistry | Tempest Therapeutics, Inc. · patent 12,215,093 granted from it |
| Feb 8, 2024 | 2024/0041837 | TRIAZOLONE COMPOUNDS AND USES THEREOF | Pharmaceuticals | Tempest Therapeutics, Inc. |
| Jul 27, 2023 | 2023/0234943 | TREX1 INHIBITORS AND USES THEREOF | Organic fine chemistry | Tempest Therapeutics, Inc. |
| Feb 9, 2023 | 2023/0045612 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | Organic fine chemistry | Tempest Therapeutics, Inc. · patent 11,795,156 granted from it |
| Dec 16, 2021 | 2021/0387985 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | Organic fine chemistry | Tempest Therapeutics, Inc. · patent 11,638,704 granted from it |
| Jan 28, 2021 | 2021/0024491 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | Organic fine chemistry | Tempest Therapeutics, Inc. · patent 11,472,789 granted from it |
| Jan 14, 2021 | 2021/0008046 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | Organic fine chemistry | Tempest Therapeutics, Inc. · patent 11,738,009 granted from it |
| Sep 10, 2020 | 2020/0283438 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | Organic fine chemistry | Tempest Therapeutics, Inc. · patent 11,066,405 granted from it |
| Aug 13, 2020 | 2020/0255372 | SOLID DRUG FORM OF N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL)METHYL)UREA HYDROCHLORIDE AND COMPOSITIONS, METHODS AND KITS RELATED THERETO | Pharmaceuticals | Millendo Therapeutics, Inc. |
What it applied for, 2024 to 2025: Organic fine chemistry 2 · Pharmaceuticals 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.